Cagrilintide vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | MGF (Mechano Growth Factor) |
|---|---|---|
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |